Holen Sie sich die Stockscreener-App
16.54
0.37%
-0.13
Schlusskurs vom Vortag:
$16.41
Offen:
$16.64
24-Stunden-Volumen:
84,211
Relative Volume:
0.13
Marktkapitalisierung:
$882.48M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-52.61%
1M Leistung:
-57.17%
6M Leistung:
+55.86%
1J Leistung:
+76.19%
1-Tages-Spanne:
$16.27
$16.98
1-Wochen-Bereich:
$13.50
$17.50
52-Wochen-Spanne:
$5.83
$44.60
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Firmenname
Zenas Biopharma Inc
Sektor
Branche
Telefon
857-271-2954
Adresse
852 WINTER STREET, SUITE 250, WALTHAM
Vergleichen Sie ZBIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
16.44 | 880.88M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.36 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
811.17 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
407.74 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
811.36 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.32 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-20 | Eingeleitet | Wedbush | Outperform |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-05 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-10-08 | Eingeleitet | Citigroup | Buy |
| 2024-10-08 | Eingeleitet | Guggenheim | Buy |
| 2024-10-08 | Eingeleitet | Jefferies | Buy |
| 2024-10-08 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Zenas Biopharma Inc Aktie (ZBIO) Neueste Nachrichten
Why Zenas BioPharma Inc. stock is favored by top institutionsJuly 2025 Analyst Calls & Long Hold Capital Preservation Plans - ulpravda.ru
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc.ZBIO - PR Newswire
What insider trading reveals about Zenas BioPharma Inc. stock2025 Technical Overview & Consistent Income Trade Recommendations - ulpravda.ru
Will Zenas BioPharma Inc. stock benefit from upcoming earnings reportsWeekly Investment Recap & Safe Investment Capital Preservation Plans - ulpravda.ru
Will Zenas BioPharma Inc. stock reach Wall Street targetsRisk Management & Reliable Momentum Entry Alerts - ulpravda.ru
Is Zenas BioPharma Inc. stock a bargain at current levels2025 Price Momentum & Weekly High Momentum Picks - ulpravda.ru
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Investors to Inquire about Securities Investigation - ACCESS Newswire
Zenas BioPharma Touts Phase 3 Win, But Stock Crashes - Yahoo Finance UK
ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study - sharewise.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas ... - Bluefield Daily Telegraph
Morgan Stanley Downgrades Zenas BioPharma (ZBIO) Rating and Pric - GuruFocus
Zenas BioPharma (NASDAQ:ZBIO) Trading Down 15.5% Following Analyst Downgrade - MarketBeat
Zenas BioPharma stock slides again premarket after INDIGO Phase 3 data sparks fresh scrutiny - TechStock²
Zenas’s Obexelimab Meets Phase III Endpoint In IgG4-RD But Trails Amgen Rival - Citeline News & Insights
Zenas Biopharma stock maintains Buy rating at H.C. Wainwright after positive trial data - Investing.com Canada
Why Zenas BioPharma's Selloff Was Structurally Inevitable - Benzinga
Zenas’ stock drops 51% despite lead asset’s Phase III rare disease win - Yahoo Finance
Jefferies lowers Zenas Biopharma stock price target to $48 on trial data - Investing.com Canada
Why Is ZBIO Stock Falling Pre-Market Today? - Stocktwits
Zenas: Maintaining 'Strong Buy' As Cross-Trial Comparison Of Obexelimab Should Not Be A Factor - Seeking Alpha
How Much Could Obexelimab’s Phase 3 Win Reshape Zenas BioPharma’s (ZBIO) Autoimmune Franchise Ambitions? - Yahoo Finance
Zenas BioPharma Stock Pre-Market (-4.0%) : Fallout From Phase 3 Data Disappointment - Trefis
Zenas BioPharma's immune disorder drug meets main goal in late-stage trial, ETPharma - ETPharma.com
Zenas BioPharma’s immune disorder drug meets main goal in late-stage trial - whbl.com
A Look At Zenas BioPharma (ZBIO) Valuation After Recent Volatility And Premium Price To Book Ratio - Sahm
Zenas Biopharma stock rating downgraded by Morgan Stanley on trial results - Investing.com Canada
Zenas BioPharma, A Top 1% Stock, Quadrupled In 2025. Why It Just Collapsed. - Investor's Business Daily
Zenas BioPharma (NASDAQ:ZBIO) Downgraded to "Equal Weight" Rating by Morgan Stanley - MarketBeat
Zenas BioPharma Stock Plummets 57% Despite Positive Phase 3 INDIGO Results - Nasdaq
Zenas BioPharma (NASDAQ:ZBIO) Shares Gap DownHere's Why - MarketBeat
Obexelimab’s Strong Phase 3 Data and Differentiated Positioning Underpin Zenas BioPharma Buy Rating and $44 Target - TipRanks
Zenas Bio Inflammation Drug Meets Phase 3 Goals, But Is It Enough to Compete With Amgen? - MedCity News
Zenas BioPharma Shares Phase III INDIGO Win as Obexelimab Cuts IgG4-RD Flare Risk 56% - MarketBeat
Zenas BioPharma announces positive phase 3 Obexelimab results - MSN
Indigo grills: Street querying Zenas phase III IgG4-RD beat - BioWorld MedTech
Zenas shares crash after top drug misses expectations in immune disease study - BioPharma Dive
Zenas shares plunge on weaker-than-expected data for immune disorder drug - marketscreener.com
Zenas crashes as late-stage trial data for lead asset disappoint - MSN
Zenas posts late-stage trial data for lead asset (ZBIO:NASDAQ) - Seeking Alpha
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zenas BioPharma, Inc. (NASDAQ: ZBIO) - PR Newswire
Zenas BioPharma's immune disorder drug meets main goal in late-stage trial - TradingView — Track All Markets
Zenas BioPharma Announces Positive Phase 3 Obexelimab Results - TipRanks
Zenas BioPharma stock falls after Phase 3 trial results By Investing.com - Investing.com Canada
Zenas BioPharma’s obexelimab shows 56% reduction in IgG4-RD flares By Investing.com - Investing.com Canada
Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) - The Manila Times
Experimental IgG4-related disease drug sharply cuts flare risk in trial - Stock Titan
Zenas BioPharma, Inc. (ZBIO) Stock Analysis: A Promising 34.95% Upside in the Biotech Arena - DirectorsTalk Interviews
Zenas BioPharma stock slides 5% today as biotech shares sag; Phase 3 INDIGO data in focus - ts2.tech
Zenas BioPharma (ZBIO) stock steadies in premarket after 8% slide as INDIGO trial timing stays in focus - ts2.tech
Zenas BioPharma (NASDAQ:ZBIO) Shares Down 6.4%Here's Why - MarketBeat
Finanzdaten der Zenas Biopharma Inc-Aktie (ZBIO)
Es liegen keine Finanzdaten für Zenas Biopharma Inc (ZBIO) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Zenas Biopharma Inc-Aktie (ZBIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner |
Oct 09 '25 |
Buy |
19.00 |
126,315 |
2,399,985 |
1,917,895 |
| ENRIGHT PATRICK G | Director |
Oct 09 '25 |
Buy |
19.00 |
105,265 |
2,000,035 |
1,832,669 |
| ENRIGHT PATRICK G | Director |
Oct 09 '25 |
Buy |
20.85 |
11,990 |
249,992 |
11,990 |
| MOULDER LEON O JR | See Remarks |
Oct 07 '25 |
Buy |
20.85 |
36,928 |
769,949 |
36,928 |
| Fairmount Funds Management LLC | Director |
Oct 07 '25 |
Buy |
19.00 |
316,219 |
6,008,161 |
2,209,025 |
| Lu Hongbo | Director |
Oct 07 '25 |
Buy |
19.00 |
263,160 |
5,000,040 |
321,983 |
| MOULDER LEON O JR | Chief Executive Officer |
Feb 18 '25 |
Buy |
6.67 |
25,000 |
166,750 |
266,155 |
| Xiao Ting | Director |
Feb 07 '25 |
Buy |
7.76 |
10,000 |
77,600 |
47,000 |
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):